| Formulary Amendments |
| Last updated: 11th February 2025 |
| Chapter |
Change |
Traffic light
status |
Reason for change |
| 06.01.06 |
Note added to Freestyle Libre 2 : DO NOT INITIATE IN NEW PATIENTS AS BEING DISCONTINUED IN SUMMER 2025 |
 |
Discontinuation notice |
| 13.06.01 |
trifarotene (Aklief®) cream added as an alternative to other available retinoids in patients with facial and / or truncal acne, either in combination with other topical therapies, or as monotherapy where a fixed combination product is not tolerated, or one component is contraindicated. |
 |
NENC Medicines Committee (April 2023) |
| 4 |
Tier 3 weight management services commissioning policy added to Chapter 4 and Semaglutide, Liraglutide entries |
n/a |
New NENC Policy |
| 04.10.02 |
Smoking Cessation Therapy: Cytisine is now referred to as Cytisinicline (Cytisine) |
|
BNF nomenclature |
| 14 |
The following vaccinations should not be prescribed on the NHS exclusively for the purposes of travel:
• hepatitis B • Japanese encephalitis • meningitis ACWY
• yellow fever • tick-borne encephalitis • rabies • BCG.
|
n/a |
NENC Medicines Committee (December 2024) |
| 04.07.02 |
Tramadol and paracetamol combination products now Not Approved for use, the BLACK status should primarily apply to new patients but, where appropriate, de-prescribing in existing patients should be undertaken. |
 |
NENC Medicines Committee (December 2024) |
| 04.07.02 |
Oxycodone + Naloxone combination products now Not Approved. The BLACK status should primarily apply to new patients but, where appropriate, de-prescribing in existing patients should be undertaken. |
|
NENC Medicines Committee (December 2024) |
| 04.07.02 |
Fentanyl sublingual tablets (Abstral®) restricted to use for breakthrough / rescue pain relief in palliative care on recommendation of a pain specialist or palliative care team.
|
|
NENC Medicines Committee (December 2024) |
| 05.01.03 |
Minocycline for the treatrment of acne is Not Approved. Do not initiate for new patients and deprescribe where possible in existing patients |
|
NENC Medicines Committee (December 2024) |
| 09.08 |
Ubidecarenone DO NOT PRESCRIBE for new patients and where appropriate, undertake deprescribing in existing patients. Approval for use in lipid clinic removed. |
|
NENC Medicines Committee (December 2024) |
| 15.01.08 |
Dantrolene Sodium 120mg vial added |
 |
NENC Medicines Committee (December 2024) |
| 01.02 |
Mebeverine 50mg/5ml Oral Suspension updated "Should only be used in patients unable to use solid dosage forms" |
|
NENC Medicines Committee (December 2024) |
| 04 |
All valproate containing products updated with new restrictions for male patients. |
|
NENC Medicines Committee (December 2024) |
| 07.03.02.03 |
(Levosert®) contraceptive indication updated to reflect 8 year effective duration |
|
NENC Medicines Committee (December 2024) |
| 06.04.01.02 |
Note added to both Norethisterone and Medroxyprogesterone "Should not be prescribed for menstrual delay for non clinical reasons" |
|
NENC Medicines Committee (December 2024) |
| 04.04 |
Methylphenidate 2mg/ml oral solution sugar free (Consilient Health Ltd) added. Only for those patients unable to take solid dosage forms across the whole dosage range. |
 |
NENC Medicines Committee (December 2024) |
| 09.06.07 |
Paravit-CF added for fat soluble vitamin supplementation in CF patients |
|
NENC Medicines Committee (December 2024) |
| 18.08.03 |
Skinnies® elasticated viscose garments added |
|
NENC Medicines Committee (December 2024) |
| 04.07.02 |
Sufentanil added for use during dressing changes in burns patients. |
|
NENC Medicines Committee (December 2024) |
| 08.01.03 |
Trifluridine and tipiracil updated to include indication for treating metastatic colorectal cancer in adults who have had 2 lines of treatment |
|
NICE TA1008 |
| 08.01.05 |
Rucaparib updated to include indication for maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults |
|
NICE TA1007 |
| 08.01.05 |
Futibatinib added for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement |
|
NICE TA1005 |
| 09.01 |
Exagamglogene Autotemcel added for treating transfusion-dependent beta-thalassaemia in people 12 years and over |
|
NICE TA1003 |
| 02.12 |
Evinacumab added for treating homozygous familial hypercholesterolaemia (HoFH) in people 12 years and over |
|
NICE TA1002 |
| 08.01.05 |
Zanubrutinib updated to include indication for treating marginal zone lymphoma in adults |
|
NICE TA1001 |
| 09.01.03 |
Iptacopan added for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic anaemia |
|
NICE TA1000 |
| 07.04.02 |
Vibegron added for treating symptoms of overactive bladder syndrome in adults |
|
NICE TA999 |
|
01.05.03
|
Risankizumab updated to include indication for treating moderately to severely active ulcerative colitis in adults |
|
NICE TA998 |
| 08.01.05 |
Pembrolizumab updated to include indication for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma |
|
NICE TA997 |
| 06.07.02 |
Linzagolix added for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age |
|
NICE TA996 |
| 08.03.04.02 |
Relugolix added for treating prostate cancer in adults |
|
NICE TA995 |
| 06.06.02 |
Burosumab updated to include indication for treating X‑linked hypophosphataemia (XLH) in adults |
|
NICE TA993 |
| 06.06.01 |
Abaloparatide added for treating osteoporosis after menopause |
|
NICE TA991 |
| 04.03.01 |
Trimipramine now not to be initiated for new patients and deprescribed in existing patients where possible. |
|
NENC Medicines Committee (October 2024) |
| 18.08.03 |
Silk garments not approved for use |
|
NENC Medicines Committee (October 2024) |
| 10.03.02 |
Rubefacients not approved for use |
|
NENC Medicines Committee (October 2024) |
| 02.05.05.01 |
Perindopril Arginine not approved for use |
|
NENC Medicines Committee (October 2024) |
| 02.12 |
Omega-3 Fatty acid compounds (except Vazkepa) not approved for use |
|
NENC Medicines Committee (October 2024) |
| 09 |
Lutein and Antioxidants preparations not approved for use |
|
NENC Medicines Committee (October 2024) |
| 09 |
Glucosamine and Chondroitin not approved for use. |
|
NENC Medicines Committee (October 2024) |
| 02.05.04 |
Doxazosin MR not approved for use. |
|
NENC Medicines Committee (October 2024) |
| 04.03.01 |
Dosulepin now not to be initiated for new patients and deprescribed in existing patients where possible. |
|
NENC Medicines Committee (October 2024) |
| 04.07.01 |
Co-proxamol now classed as a medicines of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 13.02.01 |
Bath and shower preparations for dry and pruritic skin conditions classed as medicines of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 02.05.05.03 |
Aliskiren now classed as a medicine of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 05.02.01 |
Off label indication for treatment of non-invasive fungal infections using the voriconazole 100mg tablets ONLY |
|
NENC Medicines Committee (October 2024) |
| 02.08.02 |
Following statement added to all DOAC listings: "In the absence of a specific clinical reason to select a particular DOAC, choose the most effective DOAC first. Rivaroxaban 'cost effective once daily for non-valvular AF' and Apixaban 'cost effective twice daily choice for non-valvular AF' " |
|
NENC Medicines Committee (October 2024) |
| 13.04.01 |
Removal of calcipotriol scalp solution as now discontinued |
|
NENC Medicines Committee (October 2024) |
| 06.04.02 |
Removal of tradename (Nebido) from testosterone undecanoate 1g/4ml as generics now available |
|
NENC Medicines Committee (October 2024) |
| 01.06.07 |
Prucalopride RAG status changed from GREEN to GREEN+ |
|
NENC Medicines Committee (October 2024) |
| 07.02.01 |
Removal of trademark from estriol 1mg/g (0.1%) cream and clarification of dosage statement |
|
NENC Medicines Committee (October 2024) |
| 01 |
Atropine 500microgram in 5ml mixture removed from formulary |
|
NENC Medicines Committee (October 2024) |
| 11.06 |
Latanoprost 0.005% with Timolol 0.5% eye drops preservative free (Fixapost) added as a PF option |
|
NENC Medicines Committee (October 2024) |
| 04.06 |
Additional off-license indication (use in children under 12yrs / longer term use, when required, for the prevention of nausea and vomiting in paediatric patients undergoing haematopoietic stem cell transplantation (HSCT)) added to aprepitant 80mg and 125mg capsules |
|
NENC Medicines Committee (October 2024) |
| 04.10.02 |
Smoking Cessation Therapy entry to replace individual NRT products |
|
NENC Medicines Committee (October 2024) |
| 04.12 |
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy |
|
NICE TA984 |
| 08.01.05 |
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (not recommended) |
|
NICE TA983 |
| 10.01.03 |
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) |
|
NICE TA982 |
| 08.01.05 |
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation |
|
NICE TA979 |
| 11.08.02 |
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion |
|
NICE TA1004 |
| 07.04.02 |
North of Tyne, Gateshead & North Cumbria: Urinary Continence Enablement Products and Devices Formulary 2024 |
|
NENC Guidelines Group (October 2024) |
| 04.07 |
NENC Clinical Pain Network: Position Statement on Chronic Pain Guidelines |
|
NENC Guidelines Group (October 2024) |
| 06.04.01.01 |
NENC ICB-wide Menopause guidance - update |
|
NENC Guidelines Group (October 2024) |
| 09.05.01.03 |
NENC ICB-wide Management of Hypomagnesaemia in adults |
|
NENC Guidelines Group (October 2024) |
| 09.04 |
NENC ICB-wide Guidelines for the appropriate prescribing of Oral Nutritional Supplementation in the management of adults at risk of undernutrition in primary care |
|
NENC Guidelines Group (October 2024) |
| 13.02.01 |
NENC ICB-wide Emollient Prescribing Guideline and Formulary added |
|
NENC Guidelines Group (October 2024) |
| 08.01.05 |
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (not recommended) |
|
NICE TA992 |
| 02.11 |
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B |
|
NICE TA989 |
| 08.01.05 |
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) |
|
NICE TA987 |
| 13.05.03 |
Lebrikizumab for treating moderate to severe atopic dermatitis |
|
NICE TA986 |
| 19 |
QuiremSpheres for treating unresectable advanced hepatocellular carcinoma |
|
NICE TA985 |
| 01.05.03 |
Risankizumab for treating moderately to severely active ulcerative colitis |
|
NICE TA998 |
| 02.05.01 |
Sildenafil - amendment of secondary Raynaud's to Raynaud's |
|
NENC Medicines Committee (August 2024) |
| 02.10.02 |
Tenecteplase for treating acute ischaemic stroke |
|
NICE TA990 |
| 03.09.01 |
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) |
|
NICE TA969 |
| 04.01.01 |
Daridorexant - addition of NHCFT to list of providers |
|
NENC Medicines Committee (August 2024) |
| 04.03.03 |
Fluoxetine 10mg capsules - addition of formulation |
|
NENC Medicines Committee (August 2024) |
| 04.06 |
Doxylamine & pyrodoxine for use in nausea and vomiting in pregnancy |
|
NENC Medicines Committee (August 2024) |
| 04.07.02 |
Morphine sulfate oro-dispersible tablets (Actimorph) added and Sevredol removed |
|
NENC Medicines Committee (August 2024) |
| 04.07.04.02 |
Atogepant for preventing migraine |
|
NICE TA973 |
| 05 |
Addition of link for cellulitis diagnosis and management |
|
NENC Medicines Committee (August 2024) |
| 05.03.01 |
Addition of bictegravir, emtricitabine, tenofovir alafenamide (Biktarvy®) |
|
Correction of missing entry |
| 06.03.02 |
Hydrocortisone oral solution & merged entries |
|
NENC Medicines Committee (August 2024) |
| 06.04.01.02 |
Progesterone - Addition of Utrogestran vaginal capsules and clarification of use in relation to NICE NG25 |
|
NENC Medicines Committee (August 2024) |
| 06.07 |
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome |
|
NICE HST31 |
| 07.04.02 |
Vibegron for treating symptoms of overactive bladder syndrome |
|
NICE TA999 |
| 08.01.05 |
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma |
|
NICE TA964 |
| 08.01.05 |
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over |
|
NICE TA977 |
| 08.01.05 |
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
|
NICE TA963 |
| 08.01.05 |
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) |
|
NICE TA968 |
| 08.01.05 |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over |
|
NICE TA967 |
| 08.01.05 |
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) |
|
NICE TA966 |
| 08.01.05 |
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma |
|
NICE TA974 |
| 08.01.05 |
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) |
|
NICE TA976 |
| 08.01.05 |
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) |
|
NICE TA978 |
| 08.02.02 |
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) |
|
NICE TA972 |
| 09.01.01.01 |
Addition of position statement for oral iron supplementation for iron deficiency anaemia |
|
NENC Medicines Committee (August 2024) |
| 10.02.02 |
Quinine Sulfate - addition of 200mg tablets |
|
NENC Medicines Committee (August 2024) |
| 11.04.01 |
Hydroortisone Sodium Phosphate eye drops for patients who require a preservative-free low potency ocular corticosteroid |
|
NENC Medicines Committee (August 2024) |
| 13.05.03 |
Pimecrolimus cream - additional wording to clarify initiation |
|
NENC Medicines Committee (August 2024) |
| 13.05.03 |
Tacrolimus ointment - additional wording to clarify initiation |
|
NENC Medicines Committee (August 2024) |
| 15.01.01 |
Ketamine in palliative care - changed from Amber to Red |
|
NENC Medicines Committee (August 2024) |
